BlackRock’s Indivior Pharmaceuticals INDV Stock Holding History

BlackRock’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$768M	Buy	18,709,432 +167,212	+0.9%	+$6.07M	0.01%	912
2026 Q1	$565M	Buy	18,542,220 +311,681	+2%	+$10.3M	0.01%	1009
2025 Q4	$654M	Buy	18,230,539 +9,501,401	+109%	+$290M	0.01%	926
2025 Q3	$210M	Buy	8,729,138 +3,044,560	+54%	+$63.7M	﹤0.01%	1636
2025 Q2	$83.8M	Buy	5,684,578 +5,617,001	+8,312%	+$65.4M	﹤0.01%	2161
2025 Q1	$644K	Sell	67,577 -36,059	-35%	-$379K	﹤0.01%	4323
2024 Q4	$1.29M	Buy	+103,636	New	+$1.07M	﹤0.01%	4162
2024 Q1	–	Sell	-82	Closed	-$1.25K	–	5330
2023 Q4	$1.25K	Sell	82 -8	-9%	-$142	﹤0.01%	5256
2023 Q3	$2.08K	Buy	+90	New	+$2.05K	﹤0.01%	5297

Other funds holding INDV

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

BlackRock's INDV Position: Q2 2026 in Review

BlackRock increased its Indivior Pharmaceuticals (INDV) stake by 0.9% in Q2 2026, buying an estimated $6.07M and bringing the position to 18,709,432 shares worth $768M. The position accounts for 0.01% of the portfolio, ranked #912.

BlackRock first reported a position in INDV in Q3 2023 and has held it in 9 quarters since. 336 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

BlackRock held 18,709,432 shares of Indivior Pharmaceuticals worth $768M as of Q2 2026.
BlackRock bought 167,212 Indivior Pharmaceuticals shares in Q2 2026, an estimated $6.07M.
Indivior Pharmaceuticals made up 0.01% of BlackRock's portfolio in Q2 2026, its #912 holding.
BlackRock first reported a position in Indivior Pharmaceuticals in Q3 2023 and has held it in 9 quarters since.
336 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.